{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:57:41Z","timestamp":1786467461778,"version":"build-2736575974"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rare and ultra-rare genetic diseases (GDs) involve complex, multidimensional burdens not fully captured by clinical endpoints, highlighting uncertainties in the availability, scope, and quality of Health-Related Quality-of-life patient-reported outcome measures (HRQoL-PROMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To identify PROMs developed or validated to assess HRQoL in rare and ultra-rare GDs, map their content using the International Classification of Functioning, Disability and Health (ICF), and evaluate their measurement properties according to COSMIN methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Original studies reporting PROM development or measurement properties in rare or ultra-rare GDs were included. PubMed, Embase, PsycINFO, Web of Science, registries, outcome-measure repositories, reference lists, and citation tracking were searched from inception to March 26, 2026, without language restrictions. Study selection, data extraction, and risk-of-bias (RoB) assessment were performed independently. Methodological quality was evaluated using the COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) RoB checklist. Measurement properties were rated as sufficient, insufficient, indeterminate, or inconsistent, and certainty of evidence was assessed using a modified GRADE approach. PROM content was mapped to ICF components and synthesized narratively; no meta-analysis was conducted due to heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-nine studies were included, covering 45 PROMs across 29 rare or ultra-rare GDs. Instruments were predominantly disease-specific, although generic and adapted measures were also identified. PROMs mainly addressed body functions and activities\/participation, while environmental factors, social participation, stigma, and access-to-care domains were consistently underrepresented. Internal consistency and construct validity were most frequently assessed, whereas responsiveness, measurement error, and cross-cultural validity were rarely evaluated. Only three PROMs (HAE-QoL, NF1-AdQoL, EPP-QoL) were classified as COSMIN category A and recommended; most were category B, and five were category C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The evidence is limited and methodologically weak, and many QoL-PROMs fail to capture key multidimensional aspects of QoL; more rigorous, patient-centered, disease-specific development and validation are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain language summary<\/jats:title>\n                    <jats:p>This review examined questionnaires used to assess health related quality of life in people with rare and ultra-rare genetic diseases. Although 45 PROMs were identified, only three had enough evidence to be recommended. Many questionnaires focused mainly on symptoms and physical functioning, while important aspects such as social participation, stigma, care access, and environmental support were often missing. Future PROMs should be developed with strong patient involvement and validated across age groups, languages, and disease contexts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01155-5","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:15:46Z","timestamp":1784967346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Self-reported perspective in rare genetic diseases: a systematic review of patient-reported outcome measures classified using the international classification of functioning, disability and health framework"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0529-354X","authenticated-orcid":false,"given":"Rachele","family":"Simeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5339-2501","authenticated-orcid":false,"given":"Marina","family":"Usai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Tramonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Canova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Frigerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0670-5303","authenticated-orcid":false,"given":"Anna","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9880-2241","authenticated-orcid":false,"given":"Elisa","family":"Pelosin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6009-4350","authenticated-orcid":false,"given":"Carola","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"1155_CR1","doi-asserted-by":"publisher","unstructured":"Baynam G, Hartman AL, Letinturier MCV, Bolz-Johnson M, Carrion P, Grady AC, Dong X, Dooms M, Dreyer L, Graessner H, Granados A, Groza T, Houwink E, Jamuar SS, Vasquez-Loarte T, Tumiene B, Wiafe SA, Bjornson-Pennell H, Groft S (2024) Global health for rare diseases through primary care. Lancet Global Health 12(7):e1192\u2013e1199. https:\/\/doi.org\/10.1016\/S2214-109X(24)00134-7","DOI":"10.1016\/S2214-109X(24)00134-7"},{"issue":"1","key":"1155_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","volume":"13","author":"A Slade","year":"2018","unstructured":"Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J, Lipkin G, Calvert M (2018) Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis 13(1):61. https:\/\/doi.org\/10.1186\/s13023-018-0810-x","journal-title":"Orphanet J Rare Dis"},{"key":"1155_CR3","doi-asserted-by":"publisher","unstructured":"Lancet Global Health T, Lancet Glob. Health (2024) The landscape for rare diseases in 2024. Lancet Global Health 12(3):e341. https:\/\/doi.org\/10.1016\/S2214-109X(24)00056-1","DOI":"10.1016\/S2214-109X(24)00056-1"},{"key":"1155_CR4","unstructured":"European Union. Union PO of the E (2003) CELEX1, decision No 1295\/1999\/EC of the European Parliament and of the council of 29 April 1999 adopting a programme of community action on rare diseases within the framework for action in the field of public health (1999 to 2003). https:\/\/op.europa.eu\/en\/publication-detail\/-\/publication\/208111e4-414e-4da5-94c1-852f1c74f351"},{"key":"1155_CR5","doi-asserted-by":"publisher","unstructured":"Dumbuya JS, Zeng C, Deng L, Li Y, Chen X, Ahmad B, Lu J (2025) The impact of rare diseases on the quality of life in paediatric patients: current status. Front Public Health 13. https:\/\/doi.org\/10.3389\/fpubh.2025.1531583","DOI":"10.3389\/fpubh.2025.1531583"},{"key":"1155_CR6","unstructured":"Fda, Cder (2020) Patient-focused drug development: collecting comprehensive and representative input guidance for industry, food and drug administration staff, and other stakeholders. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/guidances-drugsand\/or"},{"key":"1155_CR7","doi-asserted-by":"publisher","unstructured":"Delaye J, Cacciatore P, Kole A (2022) Valuing the \u201cburden\u201d and impact of rare diseases: a scoping review. Front Pharmacol 13. https:\/\/doi.org\/10.3389\/fphar.2022.914338","DOI":"10.3389\/fphar.2022.914338"},{"key":"1155_CR8","unstructured":"International classification of functioning, disability, and health (2001) ICF. Preprint at https:\/\/search.library.wisc.edu\/catalog\/999977181002121"},{"issue":"5","key":"1155_CR9","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3109\/09638288.2016.1145258","volume":"41","author":"A Cieza","year":"2019","unstructured":"Cieza A, Fayed N, Bickenbach J, Prodinger B (2019) Refinements of the ICF linking rules to strengthen their potential for establishing comparability of health information. Disabil Rehabil 41(5):574\u2013583. https:\/\/doi.org\/10.3109\/09638288.2016.1145258","journal-title":"Disabil Rehabil"},{"issue":"4","key":"1155_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/16501970510040263","volume":"37","author":"A Cieza","year":"2005","unstructured":"Cieza A, Geyh S, Chatterji S, Kostanjsek N, \u00dcst\u00fcn B, Stucki G (2005) ICF linking rules: an update based on lessons learned. J Rehabil Med 37(4):212\u2013218. https:\/\/doi.org\/10.1080\/16501970510040263","journal-title":"J Rehabil Med"},{"issue":"11","key":"1155_CR11","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s11136-024-03761-6","volume":"33","author":"LB Mokkink","year":"2024","unstructured":"Mokkink LB, Elsman EB, Terwee CB (2024) COSMIN guideline for systematic reviews of patient-reported outcome measures version 2.0. Qual Life Res 33:2929\u20132939. https:\/\/doi.org\/10.1007\/s11136-024-03761-6","journal-title":"Qual Life Res"},{"key":"1155_CR12","doi-asserted-by":"publisher","unstructured":"Knoble N, Murray LT (2024) Advancing rare disease measurement through the rare disease clinical outcome assessment consortium. Ther Adv Rare Disease 5. https:\/\/doi.org\/10.1177\/26330040241307962","DOI":"10.1177\/26330040241307962"},{"key":"1155_CR13","doi-asserted-by":"publisher","unstructured":"Baroni I, Paglione G, De Angeli G, Angolani M, Callus E, Magon A, Conte G, Terzoni S, Lusignani M, Caruso R, Zanichelli A (2025) A COSMIN systematic review of instruments for evaluating health-related quality of life in people with hereditary angioedema. Health Qual Life Outcomes 23(1). https:\/\/doi.org\/10.1186\/s12955-025-02342-6","DOI":"10.1186\/s12955-025-02342-6"},{"issue":"1","key":"1155_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13023-023-02844-w","volume":"18","author":"J Feng","year":"2023","unstructured":"Feng J, Gao Z, Shi Z, Wang Y, Li S (2023) Patient-reported outcomes in Gaucher\u2019s disease: a systematic review. Orphanet J Rare Dis 18(1):244. https:\/\/doi.org\/10.1186\/s13023-023-02844-w","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"1155_CR15","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s11136-024-03634-y","volume":"33","author":"EBM Elsman","year":"2024","unstructured":"Elsman EBM et al (2024) Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024. Qual Life Res 33(8):2029\u20132046. https:\/\/doi.org\/10.1007\/s11136-024-03634-y","journal-title":"Qual Life Res"},{"issue":"1","key":"1155_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"issue":"1","key":"1155_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12874-020-01179-5","volume":"20","author":"LB Mokkink","year":"2020","unstructured":"Mokkink LB, Boers M, van der Vleuten CPM, Bouter LM, Alonso J, Patrick DL, de Vet HCW, Terwee CB (2020) COSMIN risk of bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study. BMC Med Res Methodol 20(1):293. https:\/\/doi.org\/10.1186\/s12874-020-01179-5","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"1155_CR18","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s11136-017-1765-4","volume":"27","author":"LB Mokkink","year":"2018","unstructured":"Mokkink LB, de Vet HCW, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, Terwee CB (2018) COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures. Qual Life Res 27(5):1171\u20131179. https:\/\/doi.org\/10.1007\/s11136-017-1765-4","journal-title":"Qual Life Res"},{"issue":"7","key":"1155_CR19","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/jdv.19061","volume":"37","author":"M Godeau","year":"2023","unstructured":"Godeau M, Shourick J, Dreyfus I, Casassa \u00c9, Bergeron A, Severino-Freire M, Granier Tournier C, Malloizel-Delaunay J, Boccara O, Aubert H, Maruani A, Chiaverini C, Labr\u00e8ze C, Mazereeuw-Hautier J (2023) cLFM-qol: a specific quality of life measurement tool for children from 11 to 15 years with low-flow malformations. Acad Dermatol Venereol 37(7):1435\u20131442. https:\/\/doi.org\/10.1111\/jdv.19061","journal-title":"Acad Dermatol Venereol"},{"key":"1155_CR20","doi-asserted-by":"publisher","unstructured":"Anttila H, Tallqvist S, Mu\u00f1oz M, Lepp\u00e4joki-Tiistola S, M\u00e4kitie O, Hiekkala S (2021) Towards an ICF-based self-report questionnaire for people with skeletal dysplasia to study health, functioning, disability and accessibility. Orphanet J Rare Dis 16(1). https:\/\/doi.org\/10.1186\/s13023-021-01857-7","DOI":"10.1186\/s13023-021-01857-7"},{"issue":"2","key":"1155_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/ced.14867","volume":"47","author":"H Crawford","year":"2022","unstructured":"Crawford H, North K, Wilson MJ, Berman Y, McKelvey-Martin V, Morrison PJ, Fleming J, Barton B (2022) Development and preliminary evaluation of the neurofibromatosis type 1 adult quality of life (NF1-AdQoL) questionnaire. Clin Exp Derm 47(2):271\u2013281. https:\/\/doi.org\/10.1111\/ced.14867","journal-title":"Clin Exp Derm"},{"key":"1155_CR22","doi-asserted-by":"publisher","unstructured":"de Vries PJ, Franz DN, Curatolo P, Nabbout R, Neary M, Herbst F, Sully K, Brohan E, Bennett B, Lawson JA (2018) Measuring health-related quality of life in tuberous sclerosis complex \u2013 psychometric evaluation of three instruments in individuals with refractory epilepsy. Front Pharmacol 9. https:\/\/doi.org\/10.3389\/fphar.2018.00964","DOI":"10.3389\/fphar.2018.00964"},{"issue":"1","key":"1155_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.6061\/clinics\/2013(01)OA13","volume":"68","author":"MACMS Gomide","year":"2013","unstructured":"Gomide MACMS, Toledo E, Valle SOR, Campos RA, Fran\u00e7a AT, Gomez NP, Andrade HF, Caballero T, Grumach AS (2013) Hereditary angioedema: quality of life in Brazilian patients. Clinics (Sao Paulo) 68(1):81\u201383. https:\/\/doi.org\/10.6061\/clinics\/2013(01)OA13","journal-title":"Clinics (Sao Paulo)"},{"issue":"2","key":"1155_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.61186\/jgbfnm.20.2.63","volume":"20","author":"R Jahanshahi","year":"2023","unstructured":"Jahanshahi R, Mirzaei F, Askari MH, Asgari N, Ghasemi S, Sanagoo A, Jouybari L (2023) The Persian version of neurofibromatosis type 1 adult health-related quality of life (NF1-AdQOL) questionnaire in Iranians: a validity and reliability study. J Res Dev Nurs Midw 20(2):63\u201366. https:\/\/doi.org\/10.61186\/jgbfnm.20.2.63","journal-title":"J Res Dev Nurs Midw"},{"key":"1155_CR25","doi-asserted-by":"publisher","unstructured":"Jindal NL, Harniman E, Prior N, Perez-Fernandez E, Caballero T, Betschel S (2017) Hereditary angioedema: health-related quality of life in Canadian patients as measured by the SF-36. Allergy Asthma Clin Immunol 13(1). https:\/\/doi.org\/10.1186\/s13223-016-0176-3","DOI":"10.1186\/s13223-016-0176-3"},{"key":"1155_CR26","doi-asserted-by":"publisher","unstructured":"K\u00fcgler C, Witt S, Hammersen J, Quitmann J, Schneider H (2026) Health-related quality of life of children and adolescents with the most common ectodermal dysplasia: focus group study and item development for a condition-specific patient-reported outcome measure. Orphanet J Rare Dis 21(1). https:\/\/doi.org\/10.1186\/s13023-026-04246-0","DOI":"10.1186\/s13023-026-04246-0"},{"key":"1155_CR27","doi-asserted-by":"publisher","unstructured":"Lawson McLean AC, Freier A, Lawson McLean A, Kruse J, Rosahl S (2023) The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity. Orphanet J Rare Dis 18(1). https:\/\/doi.org\/10.1186\/s13023-022-02607-z","DOI":"10.1186\/s13023-022-02607-z"},{"issue":"1","key":"1155_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-7525-11-21","volume":"11","author":"K Nutakki","year":"2013","unstructured":"Nutakki K, Hingtgen CM, Monahan P, Varni JW, Swigonski NL (2013) Development of the adult PedsQL\u2122 neurofibromatosis type 1 module: initial feasibility, reliability and validity. Health Qual Life Outcomes 11(1):21. https:\/\/doi.org\/10.1186\/1477-7525-11-21","journal-title":"Health Qual Life Outcomes"},{"key":"1155_CR29","doi-asserted-by":"publisher","unstructured":"Oliveira Machado M et al (2026) Translation and cultural adaptation of the PedsQL neurofibromatosis module, version 3.0, into Brazilian Portuguese. Cureus. https:\/\/doi.org\/10.7759\/cureus.103088","DOI":"10.7759\/cureus.103088"},{"key":"1155_CR30","doi-asserted-by":"publisher","unstructured":"Palao-Ocharan P, Prior N, P\u00e9rez-Fern\u00e1ndez E, Caminoa M, Aberer W, Betschel S, Bygum A, Campos RA, Csuka D, Farkas H, G\u00f3mez-Traseira C, Grumach AS, Leibovich I, Malbran A, Moldovan D, Mihaly E, Obtulowicz K, Porebski G, Reshef A, Staubach P, Caballero T (2022) Psychometric study of the SF-36v2 in hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE). Orphanet J Rare Dis 17(1). https:\/\/doi.org\/10.1186\/s13023-022-02202-2","DOI":"10.1186\/s13023-022-02202-2"},{"issue":"1","key":"1155_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1477-7525-10-82","volume":"10","author":"N Prior","year":"2012","unstructured":"Prior N, Remor E, G\u00f3mez-Traseira C, L\u00f3pez-Serrano C, Caba\u00f1as R, Contreras J, Campos \u00c1, Cardona V, Cimbollek S, Gonz\u00e1lez-Quevedo T, Guilarte M, de Rojas DH, Marcos C, Rubio M, Tejedor-Alonso M, Caballero T (2012) Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project. Health Qual Life Outcomes 10(1):82. https:\/\/doi.org\/10.1186\/1477-7525-10-82","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"1155_CR32","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaip.2015.12.010","volume":"4","author":"N Prior","year":"2016","unstructured":"Prior N, Remor E, P\u00e9rez-Fern\u00e1ndez E, Caminoa M, G\u00f3mez-Traseira C, Gay\u00e1 F, Aabom A, Aberer W, Betschel S, Boccon-Gibod I, Bouillet L, Bygum A, Csuka D, Farkas H, Gomide M, Grumach A, Leibovich I, Malbran A, Moldovan D, Mihaly E, Obtulowicz K, Perp\u00e9n C, Peveling-Oberhag A, Porebski G, Chavannes CR, Reshef A, Staubach P, Wiednig M, Caballero T (2016) Psychometric field study of hereditary angioedema quality of life questionnaire for adults: HAE-QoL. J Allergy Clin Immunol: Pract 4(3):464\u2013473.e4. https:\/\/doi.org\/10.1016\/j.jaip.2015.12.010","journal-title":"J Allergy Clin Immunol: Pract"},{"issue":"7","key":"1155_CR33","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1177\/13591053231221369","volume":"30","author":"G Salamon","year":"2025","unstructured":"Salamon G, Strobl S, Field-Werners U, Welponer T, Murrell DF, Diem A (2025) Translation, cultural adaptation and validation of the German quality of life in epidermolysis Bullosa (QOLEB) questionnaire. J Health Psychol 30(7):1476\u20131490. https:\/\/doi.org\/10.1177\/13591053231221369","journal-title":"J Health Psychol"},{"key":"1155_CR34","doi-asserted-by":"publisher","unstructured":"Vanya M, Watt M, Shahraz S, Kosmas CE, Rhoten S, Costa-Cabral S, Mendivil J, Devercelli G, Weller K (2023) Content validation and psychometric evaluation of the angioedema quality of life questionnaire for hereditary angioedema. J Patient Rep Outcomes 7(1). https:\/\/doi.org\/10.1186\/s41687-023-00576-w","DOI":"10.1186\/s41687-023-00576-w"},{"issue":"12","key":"1155_CR35","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.3390\/ijerph19127059","volume":"19","author":"ARV Hern\u00e1ndez","year":"2022","unstructured":"Hern\u00e1ndez ARV, Alonso FM, Mar\u00edn JA, de la Paz MP (2022) Transcultural validation of a Spanish version of the quality of life in epidermolysis Bullosa questionnaire. IJERPH 19(12):7059. https:\/\/doi.org\/10.3390\/ijerph19127059","journal-title":"IJERPH"},{"issue":"4","key":"1155_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ijwd.2020.05.012","volume":"6","author":"A Yazdanshenas","year":"2020","unstructured":"Yazdanshenas A et al (2020) The quality of life in epidermolysis bullosa (EB-QoL) questionnaire: translation, cultural adaptation, and validation into the Farsi language. Int J Women\u2019s Dermatol 6(4):301\u2013305. https:\/\/doi.org\/10.1016\/j.ijwd.2020.05.012","journal-title":"Int J Women\u2019s Dermatol"},{"issue":"4","key":"1155_CR37","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2340\/00015555-1758","volume":"94","author":"W Yuen","year":"2014","unstructured":"Yuen W, Frew J, Veerman K, Heuvel E, Murrell D, Jonkman M (2014) Health-related quality of life in epidermolysis Bullosa: validation of the Dutch QOLEB questionnaire and assessment in the Dutch population. Acta Derm Venerol 94(4):442\u2013447. https:\/\/doi.org\/10.2340\/00015555-1758","journal-title":"Acta Derm Venerol"},{"key":"1155_CR38","doi-asserted-by":"publisher","unstructured":"Cestari T, Prati C, Menegon DB, Prado Oliveira ZN, Machado MCR, Dumet J, Nakano J, Murrell DF (2016) Translation, cross-cultural adaptation and validation of the quality of life evaluation in epidermolysis Bullosa instrument in Brazilian Portuguese. Int J Dermatol 55(2). https:\/\/doi.org\/10.1111\/ijd.12819","DOI":"10.1111\/ijd.12819"},{"issue":"7","key":"1155_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s11136-009-9509-8","volume":"18","author":"MK Vernon","year":"2009","unstructured":"Vernon MK, Rentz AM, Wyrwich KW, White MV, Grienenberger A (2009) Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual Life Res 18(7):929\u2013939. https:\/\/doi.org\/10.1007\/s11136-009-9509-8","journal-title":"Qual Life Res"},{"key":"1155_CR40","doi-asserted-by":"publisher","unstructured":"Oladapo A, Ito D, Rodriguez AM, Philpott S, Krupnick R, Allen V, Hibbard C, Scully M, Ewenstein B (2023) Psychometric evaluation of a patient-reported outcomes instrument for congenital thrombotic thrombocytopenic purpura. J Patient Rep Outcomes 7(1). https:\/\/doi.org\/10.1186\/s41687-023-00592-w","DOI":"10.1186\/s41687-023-00592-w"},{"key":"1155_CR41","doi-asserted-by":"publisher","unstructured":"Biolcati G, Hanneken S, Minder EI, Neumann NJ, Wilson JHP, Wolgen PJ, Wright DJ, Lloyd AJ (2021) Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL. J Patient Rep Outcomes 5(1). https:\/\/doi.org\/10.1186\/s41687-021-00345-7","DOI":"10.1186\/s41687-021-00345-7"},{"key":"1155_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/PROM.S438892","volume":"15","author":"S Mathias","year":"2024","unstructured":"Mathias S et al (2024) Development and content validation of novel patient-reported outcome measures to assess disease severity and change in patients with erythropoietic Protoporphyria: the EPP impact questionnaire (EPIQ). Patient Relat Outcome Meas 15:17\u201330","journal-title":"Patient Relat. Outcome Meas"},{"key":"1155_CR43","doi-asserted-by":"publisher","unstructured":"Xu RH, Dong D, Luo N, Yang R, Liu J, Zhang S (2021) Investigating the added value of the EQ-5D-5L with two bolt-on items in patients with hemophilia. Front Med (Lausanne) 8. https:\/\/doi.org\/10.3389\/fmed.2021.707998","DOI":"10.3389\/fmed.2021.707998"},{"issue":"1","key":"1155_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13023-022-02426-2","volume":"17","author":"TTT Le","year":"2022","unstructured":"Le TTT, Martinent G, Dupuis-Girod S, Parrot A, Contis A, Riviere S, Chinet T, Grobost V, Espitia O, Dussardier-Gilbert B, Alric L, Armengol G, Maillard H, Leguy-Seguin V, Leroy S, Rondeau-Lutz M, Lavigne C, Mohamed S, Chaussavoine L, Magro P, Seguier J, Kerjouan M, Fourdrinoy S (2022) Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT. Orphanet J Rare Dis 17(1):281. https:\/\/doi.org\/10.1186\/s13023-022-02426-2","journal-title":"Orphanet J Rare Dis"},{"key":"1155_CR45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/PPA.S233830","volume":"14","author":"K Kaiser","year":"2020","unstructured":"Kaiser K et al (2020) Assessing preferences for rare disease treatment: qualitative development of the paroxysmal nocturnal hemoglobinuria patient preference questionnaire (PNH-PPQ\u00a9). Patient Prefer Adherence 14:705\u2013715","journal-title":"Patient Prefer Adherence"},{"key":"1155_CR46","unstructured":"Asnani M, Lipps G, Reid M (2007) Component structure of the SF-36 in Jamaicans with sickle cell disease. https:\/\/www.researchgate.net\/publication\/51420315"},{"issue":"1","key":"1155_CR47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/21642850.2021.2016411","volume":"10","author":"D Oudin Doglioni","year":"2022","unstructured":"Oudin Doglioni D, D\u2019Orengiani P-HD, L A, Galact\u00e9ros F, Gay MC (2022) Psychometric characteristics of the revised illness perception questionnaire (IPQ-R) in adults with sickle cell disease. Health Phychol Behavioral Med 10(1):60\u201380. https:\/\/doi.org\/10.1080\/21642850.2021.2016411","journal-title":"Health Phychol Behavioral Med"},{"issue":"6","key":"1155_CR48","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/01612840.2012.656823","volume":"33","author":"C Jenerette","year":"2012","unstructured":"Jenerette C, Brewer CA, Crandell J, Ataga KI (2012) Preliminary validity and reliability of the sickle cell disease health-related stigma scale. Issues Ment Health Nurs 33(6):363\u2013369. https:\/\/doi.org\/10.3109\/01612840.2012.656823","journal-title":"Issues Ment Health Nurs"},{"key":"1155_CR49","doi-asserted-by":"publisher","unstructured":"Asnani MR, Lipps GE, Reid ME (2009) Utility of WHOQOL-BREF in measuring quality of life in sickle cell disease. Health Qual Life Outcomes 7(1). https:\/\/doi.org\/10.1186\/1477-7525-7-75","DOI":"10.1186\/1477-7525-7-75"},{"issue":"6","key":"1155_CR50","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.5114\/ada.2021.108435","volume":"38","author":"N Spolak-Bobryk","year":"2021","unstructured":"Spolak-Bobryk N, Niedoszytko M, Jassem E, Che\u0142mi\u0144ska M, Lange M, Majkowicz M, Nedoszytko B, Borchet J (2021) Assessing quality of life in patients with mastocytosis: development of the disease-specific questionnaire. Postepy Dermatol Alergol 38(6):1044\u20131051. https:\/\/doi.org\/10.5114\/ada.2021.108435","journal-title":"Postepy Dermatol Alergol"},{"issue":"7","key":"1155_CR51","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00277-019-03681-3","volume":"98","author":"C Niedeggen","year":"2019","unstructured":"Niedeggen C, Singer S, Groth M, Petermann-Meyer A, R\u00f6th A, Schrezenmeier H, H\u00f6chsmann B, Br\u00fcmmendorf TH, Panse J (2019) Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and\/or paroxysmal nocturnal haemoglobinuria (QLQ-AA\/PNH)\u2014a report on phase III. Ann Hematol 98(7):1547\u20131559. https:\/\/doi.org\/10.1007\/s00277-019-03681-3","journal-title":"Ann Hematol"},{"issue":"2","key":"1155_CR52","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00277-016-2867-8","volume":"96","author":"M Groth","year":"2017","unstructured":"Groth M, Singer S, Niedeggen C, Petermann-Meyer A, R\u00f6th A, Schrezenmeier H, H\u00f6chsmann B, Br\u00fcmmendorf TH, Panse J (2017) Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and\/or paroxysmal nocturnal hemoglobinuria (QLQ-AA\/PNH)\u2014report on phases I and II. Ann Hematol 96(2):171\u2013181. https:\/\/doi.org\/10.1007\/s00277-016-2867-8","journal-title":"Ann Hematol"},{"key":"1155_CR53","doi-asserted-by":"publisher","unstructured":"Weisshaar K, Ewald H, Halter J, Gerull S, Sch\u00f6nfeld S, Senft Y, Martinez M, Leuppi-Taegtmeyer A, Khanna N, Maier B, Risitano A, Peffault de Latour R, Tichelli A, Passweg J, Drexler B (2020) Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA\/PNH). Orphanet J Rare Dis 15(1). https:\/\/doi.org\/10.1186\/s13023-020-01532-3","DOI":"10.1186\/s13023-020-01532-3"},{"key":"1155_CR54","doi-asserted-by":"publisher","unstructured":"Koto Y, Yamashita W, Lee Y, Hadano N, Kokubu C, Sakai N (2022) Development and validation of a disease-specific quality of life scale for adult patients with fabry disease in Japan. J Patient Rep Outcomes 6(1). https:\/\/doi.org\/10.1186\/s41687-022-00525-z","DOI":"10.1186\/s41687-022-00525-z"},{"key":"1155_CR55","doi-asserted-by":"publisher","unstructured":"Narita A, Koto Y, Noto S, Okada M, Ono M, Baba T, Sagara R, Sakai N (2024) Development and evaluation of a patient-reported outcome measure specific for gaucher disease with or without neurological symptoms in Japan. Orphanet J Rare Dis 19(1). https:\/\/doi.org\/10.1186\/s13023-023-02996-9","DOI":"10.1186\/s13023-023-02996-9"},{"key":"1155_CR56","doi-asserted-by":"publisher","unstructured":"Elstein D, Belmatoug N, Deegan P, G\u00f6ker-Alpan \u00d6, Hughes DA, Schwartz IVD, Weinreb N, Bonner N, Panter C, Fountain D, Lenny A, Longworth L, Miller R, Shah K, Schenk J, Sen R, Zimran A (2022) Development and validation of gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials. Orphanet J Rare Dis 17(1). https:\/\/doi.org\/10.1186\/s13023-021-02163-y","DOI":"10.1186\/s13023-021-02163-y"},{"key":"1155_CR57","doi-asserted-by":"publisher","unstructured":"Iversen K, Drivdal LM, Billaud Feragen KJ, Geirdal A (2018) Quality of life in adults with lymphedema cholestasis syndrome 1. Health Qual Life Outcomes 16(1). https:\/\/doi.org\/10.1186\/s12955-018-0972-1","DOI":"10.1186\/s12955-018-0972-1"},{"key":"1155_CR58","doi-asserted-by":"publisher","unstructured":"Regnault A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K, Bosch AM (2015) Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients\u2019 and parents\u2019 quality of life: the phenylketonuria \u2013 quality of life (PKU-QOL) questionnaires. Orphanet J Rare Dis 10(1). https:\/\/doi.org\/10.1186\/s13023-015-0261-6","DOI":"10.1186\/s13023-015-0261-6"},{"key":"1155_CR59","doi-asserted-by":"publisher","unstructured":"Jurecki E, Cunningham A, Birardi V, Gagol G, Acquadro C (2017) Development of the US English version of the phenylketonuria \u2013 quality of life (PKU-QOL) questionnaire. Health Qual Life Outcomes 15(1). https:\/\/doi.org\/10.1186\/s12955-017-0620-1","DOI":"10.1186\/s12955-017-0620-1"},{"key":"1155_CR60","doi-asserted-by":"publisher","unstructured":"van Kooten HA, Horton MC, Wenninger S, Baba\u010di\u0107 H, Schoser B, Lefeuvre C, Taouagh N, Lafor\u00eat P, Segovia S, D\u00edaz-Manera J, Claeys KG, Mongini T, Musumeci O, Toscano A, Hundsberger T, Brusse E, van Doorn PA, van der Ploeg AT, van der Beek NAME (2024) Improving outcome measures in late onset pompe disease: modified rasch-built pompe-specific activity scale. Euro J Neurol 31(12). https:\/\/doi.org\/10.1111\/ene.16397","DOI":"10.1111\/ene.16397"},{"issue":"6","key":"1155_CR61","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/jimd.12777","volume":"47","author":"MI Truninger","year":"2024","unstructured":"Truninger MI, Werner H, Landolt MA, Hahn A, Hennermann JB, Lagler FB, M\u00f6slinger D, Pfrimmer C, Rohrbach M, Huemer M (2024) The PompeQoL questionnaire: development and validation of a new measure for children and adolescents with pompe disease. J Inher Metab Disea 47(6):1348\u20131362. https:\/\/doi.org\/10.1002\/jimd.12777","journal-title":"J Inher Metab Disea"},{"issue":"3","key":"1155_CR62","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.nmd.2012.10.024","volume":"23","author":"NAME van der Beek","year":"2013","unstructured":"van der Beek NAME, Hagemans MLC, van der Ploeg AT, van Doorn PA, Merkies ISJ (2013) The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul Disord 23(3):256\u2013264. https:\/\/doi.org\/10.1016\/j.nmd.2012.10.024","journal-title":"Neuromuscul Disord"},{"key":"1155_CR63","doi-asserted-by":"publisher","unstructured":"Vinik EJ, Vinik AI, Paulson JF, Merkies ISJ, Packman J, Grogan DR, Coelho T (2014) Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripheral Nerv Sys 19(2):104\u2013114. https:\/\/doi.org\/10.1111\/jns5.12059","DOI":"10.1111\/jns5.12059"},{"issue":"4","key":"1155_CR64","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s11136-014-0833-2","volume":"24","author":"TA Kanters","year":"2015","unstructured":"Kanters TA, Redekop WK, Kruijshaar ME, van der Ploeg AT, Rutten-van M\u00f6lken MPMH, Hakkaart L (2015) Comparison of EQ-5D and SF-6D utilities in pompe disease. Qual Life Res 24(4):837\u2013844. https:\/\/doi.org\/10.1007\/s11136-014-0833-2","journal-title":"Qual Life Res"},{"key":"1155_CR65","doi-asserted-by":"publisher","unstructured":"Jovanovic A, Klassen P, Heuschmann P, Sommer C, Roberts M, \u00dc\u00e7eyler N (2020) English version of the self-administered fabry pain questionnaire for adult patients. Orphanet J Rare Dis 15(1). https:\/\/doi.org\/10.1186\/s13023-020-01580-9","DOI":"10.1186\/s13023-020-01580-9"},{"key":"1155_CR66","doi-asserted-by":"publisher","unstructured":"Andrae DA, Grace RF, Jewett A, Foster B, Klaassen RJ, Salek S, Li J, Tai F, Boscoe AN, Zagadailov E (2023) Psychometric validation of the pyruvate kinase deficiency diary and pyruvate kinase deficiency Impact assessment in adults in the phase 3 ACTIVATE trial. J Patient Rep Outcomes 7(1). https:\/\/doi.org\/10.1186\/s41687-023-00650-3","DOI":"10.1186\/s41687-023-00650-3"},{"issue":"2","key":"1155_CR67","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11136-022-03266-0","volume":"32","author":"K Kaiser","year":"2023","unstructured":"Kaiser K, Fox RS, Perschon C, Vera-Llonch M, Alonso J, Cubells L, Cella D (2023) Qualitative development of the PROMIS profile v1.0-familial chylomicronemia syndrome (FCS) 28. Qual Life Res 32(2):605\u2013614. https:\/\/doi.org\/10.1007\/s11136-022-03266-0","journal-title":"Qual Life Res"},{"key":"1155_CR68","doi-asserted-by":"publisher","unstructured":"Davidson D, Slota C, Vera-Llonch M, Brown TM, Hsieh A, Fehnel S (2021) Development of a novel PRO instrument for use in familial chylomicronemia syndrome. J Patient Rep Outcomes 5(1). https:\/\/doi.org\/10.1186\/s41687-021-00347-5","DOI":"10.1186\/s41687-021-00347-5"},{"issue":"2","key":"1155_CR69","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12311-023-01565-x","volume":"23","author":"M Tremblay","year":"2024","unstructured":"Tremblay M et al (2024) The development of a New patient-reported outcome measure in recessive ataxias: the person-reported ataxia impact scale. Cerebellum 23(2):512\u2013522. https:\/\/doi.org\/10.1007\/s12311-023-01565-x","journal-title":"Cerebellum"},{"issue":"3","key":"1155_CR70","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/jns.12397","volume":"25","author":"C Pisciotta","year":"2020","unstructured":"Pisciotta C, Ciafaloni E, Zuccarino R, Calabrese D, Saveri P, Fenu S, Tramacere I, Genovese F, Dilek N, Johnson NE, Heatwole C, Herrmann DN, Pareyson D (2020) Validation of the Italian version of the Charcot-Marie-tooth health index. J Peripheral Nerv Sys 25(3):292\u2013296. https:\/\/doi.org\/10.1111\/jns.12397","journal-title":"J Peripheral Nerv Sys"},{"issue":"6","key":"1155_CR71","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/jnnp-2013-307390","volume":"86","author":"S Ramchandren","year":"2015","unstructured":"Ramchandren S, Shy M, Feldman E, Carlos R, Siskind C (2015) Defining disability: development and validation of a mobility-disability severity index (mDSI) in charcot-marie-tooth disease. J Neurol, Neurosurg Psychiatry 86(6):635\u2013639. https:\/\/doi.org\/10.1136\/jnnp-2013-307390","journal-title":"J Neurol, Neurosurg Psychiatry"},{"issue":"2","key":"1155_CR72","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/0272989X20978390","volume":"41","author":"NL Crossnohere","year":"2021","unstructured":"Crossnohere NL, Fischer R, Lloyd A, Prosser LA, Bridges JFP (2021) Assessing the appropriateness of the EQ-5D for duchenne muscular dystrophy: a patient-centered study. Med Decis Mak 41(2):209\u2013221. https:\/\/doi.org\/10.1177\/0272989X20978390","journal-title":"Med Decis Mak"},{"issue":"3","key":"1155_CR73","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/mus.26109","volume":"58","author":"E Landfeldt","year":"2018","unstructured":"Landfeldt E, Mayhew A, Straub V, Lochm\u00fcller H, Bushby K, Lindgren P (2018) Psychometric analysis of the pediatric quality of life inventory 3.0 neuromuscular module administered to patients with duchenne muscular dystrophy: a rasch analysis. Muscle Nerve 58(3):367\u2013373. https:\/\/doi.org\/10.1002\/mus.26109","journal-title":"Muscle Nerve"},{"key":"1155_CR74","doi-asserted-by":"publisher","unstructured":"Malina J, Huessler E-M, J\u00f6ckel K-H, Boog-Whiteside E, Jeschonneck N, Schr\u00f6der B, Sch\u00fcle R, K\u00fchl T, Klebe S (2024) Development and validation of TreatHSP-QoL: a patient-reported outcome measure for health-related quality of life in hereditary spastic paraplegia. Orphanet J Rare Dis 19(1). https:\/\/doi.org\/10.1186\/s13023-023-03012-w","DOI":"10.1186\/s13023-023-03012-w"},{"key":"1155_CR75","doi-asserted-by":"publisher","first-page":"223","DOI":"10.5334\/tohm.177","volume":"4","author":"NE Carlozzi","year":"2014","unstructured":"Carlozzi NE et al (2014) HD-PRO-TRIADTM validation: a patient-reported instrument for the symptom triad of Huntington\u2019s disease. Tremor Other Hyperkinet Mov (N Y) 4:223","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"10","key":"1155_CR76","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s11136-016-1386-3","volume":"25","author":"NE Carlozzi","year":"2016","unstructured":"Carlozzi NE et al (2016) HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res 25(10):2441\u20132455. https:\/\/doi.org\/10.1007\/s11136-016-1386-3","journal-title":"Qual Life Res"},{"issue":"4","key":"1155_CR77","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/YIC.0b013e3283534fa9","volume":"27","author":"E Clay","year":"2012","unstructured":"Clay E, De Nicola A, Dorey J, Squitieri F, Aball\u00e9a S, Martino T, Tedroff J, Zielonka D, Auquier P, Verny C, Toumi M (2012) Validation of the first quality-of-life measurement for patients with Huntington\u2019s disease: the Huntington quality of life instrument. Int Clin Psychopharmacol 27(4):208\u2013214. https:\/\/doi.org\/10.1097\/YIC.0b013e3283534fa9","journal-title":"Int Clin Psychopharmacol"},{"key":"1155_CR78","doi-asserted-by":"publisher","unstructured":"Kay C, Audo I, Naujoks C, Spera C, Fischer MD, Green J, Durham T, Williamson N, Bradley H, Barclay M, Sims J, Banhazi J, Patalano F (2023) Qualitative exploration of the visual function impairments and impacts on vision-dependent activities of daily living in retinitis Pigmentosa and Leber Congenital Amaurosis: content validation of the ViSIO-PRO and ViSIO-ObsRO measures. J Patient Rep Outcomes 7(1). https:\/\/doi.org\/10.1186\/s41687-023-00610-x","DOI":"10.1186\/s41687-023-00610-x"},{"issue":"2","key":"1155_CR79","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s40123-023-00670-8","volume":"12","author":"MD Fischer","year":"2023","unstructured":"Fischer MD, Patalano F, Naujoks C, Banhazi J, Bouchet C, O\u2019Brien P, Kay C, Green J, Durham T, Bradley H, Williamson N, Barclay M, Sims J, Audo I (2023) Psychometric validation of the ViSIO-PRO and ViSIO-ObsRO in Retinitis Pigmentosa and Leber Congenital Amaurosis. Ophthalmol Ther 12(2):1359\u20131386. https:\/\/doi.org\/10.1007\/s40123-023-00670-8","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"1155_CR80","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s40123-023-00724-x","volume":"12","author":"I Audo","year":"2023","unstructured":"Audo I, Patalano F, Naujoks C, Spera C, Fischer MD, Green J, Kay C, Durham T, Williamson N, Bradley H, Barclay M, Boparai K, Banhazi J (2023) Development of novel patient-reported outcome (PRO) and observer-reported outcome (ObsRO) instruments in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA): ViSIO-PRO and ViSIO-ObsRO. Ophthalmol Ther 12(4):2069\u20132085. https:\/\/doi.org\/10.1007\/s40123-023-00724-x","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1155_CR81","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1167\/tvst.12.1.23","volume":"12","author":"BS Chen","year":"2023","unstructured":"Chen BS, Yu-Wai-Man P, Horton M (2023) Psychometric validity of the visual function index in leber hereditary optic neuropathy. Trans Vis Sci Tech 12(1):23. https:\/\/doi.org\/10.1167\/tvst.12.1.23","journal-title":"Trans Vis Sci Tech"},{"issue":"2","key":"1155_CR82","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1183\/09031936.00216214","volume":"46","author":"JS Lucas","year":"2015","unstructured":"Lucas JS, Behan L, Dunn Galvin A, Alpern A, Morris AM, Carroll MP, Knowles MR, Leigh MW, Quittner AL (2015) A quality-of-life measure for adults with primary ciliary dyskinesia: QOL\u2013PCD. Eur Respir J 46(2):375\u2013383. https:\/\/doi.org\/10.1183\/09031936.00216214","journal-title":"Eur Respir J"},{"issue":"10","key":"1155_CR83","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1513\/AnnalsATS.201603-198OC","volume":"13","author":"SD Dell","year":"2016","unstructured":"Dell SD, Leigh MW, Lucas JS, Ferkol TW, Knowles MR, Alpern A, Behan L, Morris AM, Hogg C, DunnGalvin A, Quittner AL (2016) Primary ciliary dyskinesia: first health-related quality-of-life measures for pediatric patients. Ann Am Thorac Soc 13(10):1726\u20131735. https:\/\/doi.org\/10.1513\/AnnalsATS.201603-198OC","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"1155_CR84","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/ppul.24507","volume":"54","author":"L Behan","year":"2019","unstructured":"Behan L, Leigh MW, Dell SD, Quittner AL, Hogg C, Lucas JS (2019) Validation of pediatric health-related quality of life instruments for primary ciliary dyskinesia (QOL-PCD). Pediatr Pulmonol 54(12):2011\u20132020. https:\/\/doi.org\/10.1002\/ppul.24507","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"1155_CR85","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1136\/thoraxjnl-2016-209356","volume":"72","author":"L Behan","year":"2017","unstructured":"Behan L, Leigh MW, Dell SD, Dunn Galvin A, Quittner AL, Lucas JS (2017) Validation of a health-related quality of life instrument for primary ciliary dyskinesia (QOL-PCD). Thorax 72(9):832\u2013839. https:\/\/doi.org\/10.1136\/thoraxjnl-2016-209356","journal-title":"Thorax"},{"issue":"1","key":"1155_CR86","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s13023-022-02529-w","volume":"17","author":"N Denton","year":"2022","unstructured":"Denton N, Mulberg AE, Molloy M, Charleston S, Fajgenbaum DC, Marsh ED, Howard P (2022) Sharing is caring: a call for a new era of rare disease research and development. Orphanet J Rare Dis 17(1):389. https:\/\/doi.org\/10.1186\/s13023-022-02529-w","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1155_CR87","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s13023-024-03373-w","volume":"19","author":"G Parenti","year":"2024","unstructured":"Parenti G, Fecarotta S, Alagia M, Attaianese F, Verde A, Tarallo A, Gragnaniello V, Ziagaki A, Guimaraes MJ, Aguiar P, Hahn A, Azevedo O, Donati MA, Kiec-Wilk B, Scarpa M, van der Beek NAME, Del Toro Riera M, Germain DP, Huidekoper H, van den Hout JMP, van der Ploeg AT, Baric I, Batzios S, Belmatoug N, Bordugo A, Bosch AM, Brassier A, Burlina A, Cassiman D, Chabrol B, Chronopoulou E, Couce-Pico ML, Darin N, Das AM, Debray FG, Deegan P, de Abreu Freire Diogo Matos LM, De Las Heras Montero J, Di Rocco M, Dobbelaere D et al (2024) The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for pompe disease (acid maltase deficiency, glycogen storage disease type II). Orphanet J Rare Dis 19(1):408. https:\/\/doi.org\/10.1186\/s13023-024-03373-w","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1155_CR88","doi-asserted-by":"publisher","first-page":"00139","DOI":"10.1183\/23120541.00139-2022","volume":"8","author":"J Raidt","year":"2022","unstructured":"Raidt J, Maitre B, Pennekamp P, Altenburg J, Anagnostopoulou P, Armengot M, Bloemsma LD, Boon M, Borrelli M, Brinkmann F, Carr SB, Carroll MP, Castillo-Corull\u00f3n S, Coste A, Cutrera R, Dehlink E, Destouches DMS, Di Cicco ME, Dixon L, Emiralioglu N, Erdem Eralp E, Haarman EG, Hogg C, Karadag B, Kobbernagel HE, Lorent N, Mall MA, Marthin JK, Martinu V, Narayanan M, Ozcelik U, Peckham D, Pifferi M, Pohunek P, Polverino E, Range S, Ringshausen FC, Robson E, Roehmel J, Rovira-Amigo S et al (2022) The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN. ERJ Open Res 8(3):00139\u201302022. https:\/\/doi.org\/10.1183\/23120541.00139-2022","journal-title":"ERJ Open Res"},{"key":"1155_CR89","doi-asserted-by":"publisher","unstructured":"Zuraw BL, Bork K, Bouillet L, Christiansen SC, Farkas H, Germenis AE, Grumach AS, Kaplan A, L\u00f3pez-Lera A, Magerl M, Riedl MA, Adatia A, Banerji A, Betschel S, Boccon-Gibod I, Bova M, Boysen HB, Caballero T, Cancian M, Castaldo AJ, Cohn DM, Corcoran D, Drouet C, Fukunaga A, Hide M, Katelaris CH, Li PH, Longhurst H, Peter J, Psarros F, Reshef A, Ritchie B, Selva CN, Zanichelli A, Maurer M (2025) Hereditary angioedema with normal C1 inhibitor: an updated International consensus paper on diagnosis, pathophysiology, and treatment. Clinic Rev Allerg Immunol 68(1). https:\/\/doi.org\/10.1007\/s12016-025-09027-4","DOI":"10.1007\/s12016-025-09027-4"},{"issue":"7","key":"1155_CR90","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/15265161.2023.2207512","volume":"23","author":"MS McCoy","year":"2023","unstructured":"McCoy MS (2023) Who is responsible for promoting equity in rare disease research? Am J Bioethics 23(7):83\u201385. https:\/\/doi.org\/10.1080\/15265161.2023.2207512","journal-title":"Am J Bioethics"},{"issue":"7","key":"1155_CR91","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jval.2017.05.015","volume":"20","author":"K Benjamin","year":"2017","unstructured":"Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L (2017) Patient-reported outcome and observer-reported outcome assessment in Rare disease clinical trials: an ISPOR COA emerging good practices task force report. Value Health 20(7):838\u2013855. https:\/\/doi.org\/10.1016\/j.jval.2017.05.015","journal-title":"Value Health"},{"key":"1155_CR92","doi-asserted-by":"publisher","unstructured":"Fournier H, Calcagni N, Morice-Picard F, Quintard B (2023) Psychosocial implications of rare genetic skin diseases affecting appearance on daily life experiences, emotional state, self-perception and quality of life in adults: a systematic review. Orphanet J Rare Dis 18(1). https:\/\/doi.org\/10.1186\/s13023-023-02629-1","DOI":"10.1186\/s13023-023-02629-1"},{"issue":"4","key":"1155_CR93","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s11136-020-02690-4","volume":"30","author":"M McNeill","year":"2021","unstructured":"McNeill M, Noyek S, Engeda E, Fayed N (2021) Assessing the engagement of children and families in selecting patient-reported outcomes (PROs) and developing their measures: a systematic review. Qual Life Res 30(4):983\u2013995. https:\/\/doi.org\/10.1007\/s11136-020-02690-4","journal-title":"Qual Life Res"},{"issue":"1","key":"1155_CR94","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/hex.12442","volume":"20","author":"B Wiering","year":"2017","unstructured":"Wiering B, de Boer D, Delnoij D (2017) Patient involvement in the development of patient-reported outcome measures: a scoping review. Health Expectations 20(1):11\u201323. https:\/\/doi.org\/10.1111\/hex.12442","journal-title":"Health Expectations"},{"key":"1155_CR95","doi-asserted-by":"publisher","unstructured":"Carlton J, Peasgood T, Khan S, Barber R, Bostock J, Keetharuth AD (2020) An emerging framework for fully incorporating public involvement (PI) into patient-reported outcome measures (PROMs). J Patient Rep Outcomes 4, 4(1). https:\/\/doi.org\/10.1186\/s41687-019-0172-8","DOI":"10.1186\/s41687-019-0172-8"},{"key":"1155_CR96","doi-asserted-by":"publisher","unstructured":"Cribbs KA, Blackmore LTA, Lahue BJ (2025) PCR25 PROM-ising progress? Patient-reported outcome measures in orphan labels. Value Health 28(6):S314. https:\/\/doi.org\/10.1016\/j.jval.2025.04.1348","DOI":"10.1016\/j.jval.2025.04.1348"},{"issue":"5","key":"1155_CR97","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s11136-018-1829-0","volume":"27","author":"CB Terwee","year":"2018","unstructured":"Terwee CB, Prinsen CAC, Chiarotto A, Westerman MJ, Patrick DL, Alonso J, Bouter LM, de Vet HCW, Mokkink LB (2018) COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual Life Res 27(5):1159\u20131170. https:\/\/doi.org\/10.1007\/s11136-018-1829-0","journal-title":"Qual Life Res"},{"issue":"3","key":"1155_CR98","doi-asserted-by":"publisher","first-page":"100462","DOI":"10.1016\/j.xhgg.2025.100462","volume":"6","author":"K Trzupek","year":"2025","unstructured":"Trzupek K, Bhargava R, Kuan C, Sie F, Vogel-Farley V, Hobbs K, Chung V, Diaz M, Son-Rigby C, Geraci J, Albrecht J (2025) Breaking barriers in rare disease research: the RARE-X open science Data challenge as a model for collaborative innovation and community partnership. HGG Adv 6(3):100462. https:\/\/doi.org\/10.1016\/j.xhgg.2025.100462","journal-title":"HGG Adv"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01155-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01155-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01155-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:20:09Z","timestamp":1786465209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01155-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01155-5","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"141"}}